IDH1 and cholangiocarcinoma: As previously discussed, IDH1 and IDH2 mutations establish an immunologically cold background with low lymphocyte infiltrates at the tumor site; the treatment with Ivosidenib has been proved to be able to recruit CD8+ T cells and restore immune system tumor vulnerability in cholangiocarcinoma [114].